OncoMatch/Clinical Trials/NCT07075185
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Is NCT07075185 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies KLN-1010 for multiple myeloma in relapse.
Treatment: KLN-1010 — The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: cd38-directed monoclonal antibody
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify